M&A
confidence high
sentiment neutral
materiality 0.70
Evofem secures voting agreements for Aditxt merger; Aditxt completes $2.28M preferred investment
Evofem Biosciences, Inc.
- Evofem signed voting agreements with Series E-1 stockholders and convertible noteholders to vote in favor of merger with Aditxt subsidiary Adifem.
- Aditxt completed $2.28M final preferred investment (Series F-1), meeting $5M total commitment under A&R Merger Agreement since May 2024.
- Closing conditions require majority stockholder vote and Aditxt raising ~$17M, including ~$15.2M to satisfy Evofem's senior secured noteholder.
- If Aditxt fails to secure funds, senior secured noteholder expected to block closing; no assurance conditions will be met.